S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:OTLK

Outlook Therapeutics - OTLK Stock Forecast, Price & News

$1.01
0.00 (0.00%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.00
â–Ľ
$1.02
50-Day Range
$1.01
â–Ľ
$1.33
52-Week Range
$0.68
â–Ľ
$2.12
Volume
275,224 shs
Average Volume
319,365 shs
Market Capitalization
$228.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Outlook Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
560.1% Upside
$6.67 Price Target
Short Interest
Bearish
12.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$92,506 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.31) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

934th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

159th out of 171 stocks

OTLK stock logo

About Outlook Therapeutics (NASDAQ:OTLK) Stock

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Receive OTLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OTLK Stock News Headlines

See More Headlines
Receive OTLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OTLK Company Calendar

Last Earnings
12/22/2021
Today
12/07/2022
Next Earnings (Estimated)
12/28/2022
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTLK
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+560.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-53,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.03 per share

Miscellaneous

Free Float
220,944,000
Market Cap
$228.41 million
Optionable
Not Optionable
Beta
0.66

Key Executives

  • Mr. Ralph H. Thurman (Age 73)
    Independent Exec. Chairman
  • Mr. C. Russell Trenary IIIMr. C. Russell Trenary III (Age 64)
    Pres, CEO & Director
    Comp: $622.66k
  • Mr. Lawrence A. Kenyon CPA (Age 56)
    Exec. VP, CFO, Treasurer, Company Sec. & Director
    Comp: $661.18k
  • Mr. Terry  DagnonMr. Terry Dagnon (Age 60)
    Chief Operations Officer
    Comp: $300k
  • Mr. Jeffrey  EvansonMr. Jeffrey Evanson (Age 53)
    Chief Commercial Officer
    Comp: $300k
  • Rick Gregory
    Director of Marketing & Communications
  • Ms. Alicia Tozier
    Sr. VP, Marketing & Market Access
  • Mr. Joel Prieve
    Sr. VP of Commercial Operations
  • Dr. Balu N. Balasubramanian
    Advisor
  • Ms. Elizabeth A. Yamashita (Age 61)
    Advisor













OTLK Stock - Frequently Asked Questions

Should I buy or sell Outlook Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OTLK shares.
View OTLK analyst ratings
or view top-rated stocks.

What is Outlook Therapeutics' stock price forecast for 2023?

4 brokerages have issued 12-month price targets for Outlook Therapeutics' stock. Their OTLK share price forecasts range from $6.00 to $7.00. On average, they expect the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 560.1% from the stock's current price.
View analysts price targets for OTLK
or view top-rated stocks among Wall Street analysts.

How have OTLK shares performed in 2022?

Outlook Therapeutics' stock was trading at $1.36 at the start of the year. Since then, OTLK shares have decreased by 25.7% and is now trading at $1.01.
View the best growth stocks for 2022 here
.

When is Outlook Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, December 28th 2022.
View our OTLK earnings forecast
.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) released its earnings results on Wednesday, December, 22nd. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.03.

When did Outlook Therapeutics' stock split?

Outlook Therapeutics shares reverse split on the morning of Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 15th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), OrganiGram (OGI) and CNBX Pharmaceuticals (CNBX).

What is Outlook Therapeutics' stock symbol?

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

Who are Outlook Therapeutics' major shareholders?

Outlook Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.03%), State Street Corp (0.86%), Vista Finance LLC (0.18%), Bank of New York Mellon Corp (0.16%), Two Sigma Advisers LP (0.09%) and Renaissance Technologies LLC (0.02%). Insiders that own company stock include C Russell Trenary III, Faisal Ghiath Sukhtian, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Randy H Thurman, Syntone Ventures Llc, Terry Dagnon and Yezan Munther Haddadin.
View institutional ownership trends
.

How do I buy shares of Outlook Therapeutics?

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Outlook Therapeutics' stock price today?

One share of OTLK stock can currently be purchased for approximately $1.01.

How much money does Outlook Therapeutics make?

Outlook Therapeutics (NASDAQ:OTLK) has a market capitalization of $228.41 million. The company earns $-53,160,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

How can I contact Outlook Therapeutics?

Outlook Therapeutics' mailing address is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.outlooktherapeutics.com. The company can be reached via phone at (609) 619-3990 or via email at jeremy@lifesciadvisors.com.

This page (NASDAQ:OTLK) was last updated on 12/8/2022 by MarketBeat.com Staff